Shapiro S, Parsells J L, Rosenberg L, Kaufman D W, Stolley P D, Schottenfeld D
Eur J Clin Pharmacol. 1984;26(2):143-6. doi: 10.1007/BF00630277.
In a case-control study of 1881 women with breast cancer and 1523 controls with benign conditions, 65 cases (3.5%) and 64 controls (4.2%) reported having used a drug that contained rauwolfia, giving a rate ratio estimate of 0.8 (95% confidence interval, 0.5-1.1). Use that ended more than a year previously was negatively associated with breast cancer (rate ratio, 0.5; 95% confidence interval, 0.2-0.9). The risk of breast cancer did not vary significantly according to duration of use. Nor did it vary within strata of varying base-line risk, such as age at first pregnancy. The data suggest that rauwolfia alkaloids do not increase the risk of breast cancer.
在一项针对1881名乳腺癌女性患者和1523名良性疾病对照者的病例对照研究中，65例（3.5%）患者和64名对照者（4.2%）报告曾使用过含萝芙木的药物，得出的率比估计值为0.8（95%置信区间为0.5 - 1.1）。超过一年前结束的用药与乳腺癌呈负相关（率比为0.5；95%置信区间为0.2 - 0.9）。乳腺癌风险并未因用药时长而有显著差异。在不同基线风险分层中，如首次怀孕年龄，其风险也无差异。数据表明萝芙木生物碱不会增加患乳腺癌的风险。
